We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




High Cell-Free DNA Integrity Is a Biomarker for Poor Breast Cancer Survival

By LabMedica International staff writers
Posted on 12 Oct 2021
A team of Finnish researchers has refined a liquid biopsy analysis technique to act as a more specific biomarker in order to more accurately predict poor prognosis for patients with aggressive breast cancer.

Breast cancer (BC) research has focused lately on the utilization of cell-free DNA (cfDNA) and its concentration (cfDConc) and integrity (cfDI) as potential biomarkers. More...
The cfDI describes the ratio of large and small cfDNA fragments. While the association of cfDConc and poor survival has already been recognized, studies on the prognostic value of cfDI have had contradictory results.

To clarify the situation, investigators at the University of Eastern Finland (Kuopio, Finland) evaluated the prognostic potential of cfDConc and cfDI in Eastern Finnish BC cases with a non-metastatic disease.

For this study, the investigators selected 204 Eastern Finnish BC cases with non-metastatic disease and isolated cfDNA from the serum collected at the time of diagnosis before any treatment was given. The cfDConc and cfDI were measured with a fluorometer and electrophoresis, and the results were analyzed together with 25 years of survival data from the Kuopio Breast Cancer Project (KBCP), which was initiated in the 1990s.

Results revealed that high cfDConc was not an independent prognostic factor, while high cfDI was found to be an independent prognostic factor for poor overall survival (OS) and breast cancer-specific survival (BCSS). Inclusion of cfDI in the commonly used multivariate logistic regression model improved the predictive performance.

The results showing that high cfDI was an independent prognostic factor for poor OS and BCSS and improved the predictive performance of logistic regression models demonstrated its prognostic potential.

“Our results show that together with traditional prognostic factors, measuring the integrity of cfDNA can in the future help us to identify breast cancer patients with a poor prognosis earlier and more accurately than before. This would allow patients requiring more intensive care to be placed under intensified care and monitoring earlier,” said senior author Dr. Arto Mannermaa, professor of clinical medicine at the University of Eastern Finland.

The study was published in the September 18, 2021, online edition of the journal Cancers.

Related Links:
University of Eastern Finland


New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Collection and Transport System
PurSafe Plus®
New
Gel Cards
DG Gel Cards
New
Capillary Blood Collection Tube
IMPROMINI M3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.